MX392558B - Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía. - Google Patents
Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía.Info
- Publication number
- MX392558B MX392558B MX2019013218A MX2019013218A MX392558B MX 392558 B MX392558 B MX 392558B MX 2019013218 A MX2019013218 A MX 2019013218A MX 2019013218 A MX2019013218 A MX 2019013218A MX 392558 B MX392558 B MX 392558B
- Authority
- MX
- Mexico
- Prior art keywords
- atropine
- pharmaceutical compositions
- compositions
- formulations
- free
- Prior art date
Links
- 229930003347 Atropine Natural products 0.000 title abstract 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 title abstract 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 title abstract 3
- 229960000396 atropine Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 238000009472 formulation Methods 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 abstract 2
- VBSTXRUAXCTZBQ-UHFFFAOYSA-N 1-hexyl-4-phenylpiperazine Chemical compound C1CN(CCCCCC)CCN1C1=CC=CC=C1 VBSTXRUAXCTZBQ-UHFFFAOYSA-N 0.000 abstract 1
- JACRWUWPXAESPB-QMMMGPOBSA-N Tropic acid Natural products OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762505027P | 2017-05-11 | 2017-05-11 | |
| PCT/US2018/032017 WO2018209051A1 (en) | 2017-05-11 | 2018-05-10 | Atropine pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019013218A MX2019013218A (es) | 2022-05-24 |
| MX392558B true MX392558B (es) | 2025-03-24 |
Family
ID=64096170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013218A MX392558B (es) | 2017-05-11 | 2018-05-10 | Composición oftálmica líquida estable, que comprende una solución acuosa con un tampón, un agente de tonicidad, un quelante, un modificador de la viscosidad y atropina; y el uso de la misma para el tratamiento de la miopía. |
Country Status (23)
| Country | Link |
|---|---|
| US (14) | US10251875B2 (enExample) |
| EP (2) | EP3548000B1 (enExample) |
| JP (5) | JP6557379B2 (enExample) |
| KR (1) | KR102281667B1 (enExample) |
| CN (1) | CN110621298B (enExample) |
| AU (1) | AU2018265257B2 (enExample) |
| CA (1) | CA3063228C (enExample) |
| CL (1) | CL2019003228A1 (enExample) |
| CO (1) | CO2019012893A2 (enExample) |
| CY (1) | CY1124880T1 (enExample) |
| ES (1) | ES2901140T3 (enExample) |
| HR (1) | HRP20212019T1 (enExample) |
| HU (1) | HUE056595T2 (enExample) |
| LT (1) | LT3548000T (enExample) |
| MX (1) | MX392558B (enExample) |
| PH (1) | PH12019502701A1 (enExample) |
| PL (1) | PL3548000T3 (enExample) |
| PT (1) | PT3548000T (enExample) |
| RS (1) | RS62817B1 (enExample) |
| RU (1) | RU2745603C1 (enExample) |
| SG (1) | SG11201910085UA (enExample) |
| SI (1) | SI3548000T1 (enExample) |
| WO (1) | WO2018209051A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10154923B2 (en) | 2010-07-15 | 2018-12-18 | Eyenovia, Inc. | Drop generating device |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| HK1248570A1 (zh) | 2015-05-29 | 2018-10-19 | 西德奈克西斯公司 | D2o稳定化的药物制剂 |
| AR108591A1 (es) * | 2016-05-25 | 2018-09-05 | Singapore Health Serv Pte Ltd | Composición acuosa que contiene atropina |
| EP3548000B1 (en) * | 2017-05-11 | 2021-11-10 | Vyluma Inc. | Atropine pharmaceutical compositions |
| AU2018279940B2 (en) | 2017-06-10 | 2023-12-14 | Eyenovia, Inc. | Methods and devices for handling a fluid and delivering the fluid to the eye |
| US11554115B2 (en) * | 2018-03-14 | 2023-01-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivative for treatment of triple-negative breast cancer |
| WO2019216395A1 (ja) * | 2018-05-11 | 2019-11-14 | 千寿製薬株式会社 | 眼科用組成物 |
| CN110934816B (zh) * | 2018-09-25 | 2022-04-08 | 沈阳兴齐眼科医院有限公司 | 一种提高低浓度阿托品眼用制剂稳定性的方法 |
| WO2020219707A1 (en) * | 2019-04-24 | 2020-10-29 | Allergan, Inc. | Compositions and methods for treatment of ocular conditions |
| WO2021001806A1 (en) * | 2019-07-04 | 2021-01-07 | Ocular Discovery Ltd. | Stable dipyridamole formulations with reduced impurities |
| CA3164288A1 (en) | 2019-12-11 | 2021-06-17 | Eyenovia, Inc. | Systems and devices for delivering fluids to the eye and methods of use |
| IL293859A (en) * | 2019-12-16 | 2022-08-01 | Sydnexis Inc | Ophthalmic compositions comprising d2o |
| CN110917133A (zh) * | 2019-12-23 | 2020-03-27 | 河北科技大学 | 一种治疗近视的滴眼剂及其制备方法 |
| EP4146148A1 (en) * | 2020-05-05 | 2023-03-15 | The Procter & Gamble Company | Oral care compositions comprising dicarboxylic acid |
| CN111821259A (zh) * | 2020-07-14 | 2020-10-27 | 艾尔健康眼药(辽宁)有限公司 | 一种眼用药物组合物 |
| CN111840221A (zh) * | 2020-08-25 | 2020-10-30 | 安徽博诺美科生物医药有限公司 | 一种硫酸阿托品滴眼液 |
| WO2022130033A1 (en) * | 2020-12-17 | 2022-06-23 | Sun Pharmaceutical Industries Limited | An aqueous sterile solution of atropine for ophthalmic use |
| CA3211874A1 (en) * | 2021-03-16 | 2022-09-22 | Kumaresh Soppimath | Multi-dose container for ophthalmic compositions |
| EP4088713A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| EP4088714A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
| CN113440486B (zh) * | 2021-06-02 | 2022-12-20 | 苏州欧康维视生物科技有限公司 | 一种用于预防或治疗眼科疾病的滴眼剂组合物及其制备方法 |
| CN117295491A (zh) * | 2021-09-13 | 2023-12-26 | 安徽欧普视方医药科技有限公司 | 阿托品滴眼液及其制备方法 |
| WO2023086878A1 (en) * | 2021-11-10 | 2023-05-19 | Visus Therapeutics, Inc. | Carbachol formulations to enhance anti-presbyopia effects |
| CN114129511A (zh) * | 2021-12-07 | 2022-03-04 | 河南润弘制药股份有限公司 | 一种具有改进稳定性的硫酸阿托品注射液 |
| WO2023152642A1 (en) * | 2022-02-08 | 2023-08-17 | Avaca Pharma Private Limited | Ophthalmic compositions and methods thereof |
| US20230277521A1 (en) * | 2022-03-07 | 2023-09-07 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
| CN114569551A (zh) * | 2022-03-21 | 2022-06-03 | 杭州赫尔斯科技有限公司 | 阿托品滴眼液及其制备方法 |
| WO2023201315A2 (en) * | 2022-04-14 | 2023-10-19 | TearClear Corp. | Ophthalmic agent in preservative removal device |
| CN115177584A (zh) * | 2022-07-14 | 2022-10-14 | 成都市海通药业有限公司 | 一种硫酸阿托品注射液的制备方法 |
| WO2024091789A1 (en) * | 2022-10-26 | 2024-05-02 | Vyluma Inc. | Childhood atropine for myopia progression |
| CN115998692A (zh) * | 2023-02-15 | 2023-04-25 | 苏州欧康维视生物科技有限公司 | 一种阿托品药物产品及其用途 |
| WO2025146828A1 (ja) * | 2024-01-05 | 2025-07-10 | ロート製薬株式会社 | 眼科組成物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU86521A1 (fr) | 1986-07-18 | 1988-02-02 | Oreal | Procede de teinture des cheveux avec des colorants hydroxyquinoniques et des sels metalliques |
| IL85312A (en) | 1988-02-03 | 1991-08-16 | Israel State | Injectable pharmaceutical compositions having improved stability |
| JP2617508B2 (ja) * | 1988-02-05 | 1997-06-04 | エーザイ株式会社 | 安定なジフェンヒドラミン含有水溶液 |
| US5460834A (en) * | 1991-12-13 | 1995-10-24 | Alcon Laboratories, Inc. | Combinations of polymers for use in physiological tear compositions |
| US5716952A (en) * | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| SE9401108D0 (sv) * | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| US20030129083A1 (en) | 1997-11-26 | 2003-07-10 | Advanced Medical Optics, Inc. | Multi purpose contact lens care compositions including propylene glycol or glycerin |
| US6164282A (en) | 1999-01-27 | 2000-12-26 | Allergan Sales, Inc. | Methods for restoring and/or enhancing accommodation in pseudo phakia |
| JP2004503593A (ja) * | 2000-07-14 | 2004-02-05 | アラーガン、インコーポレイテッド | 増大した溶解度を持つ治療活性成分を含む組成物 |
| US20020198209A1 (en) | 2001-05-03 | 2002-12-26 | Allergan Sales Inc. | Compositions having enhanced pharmacokinetic characteristics |
| US8758816B2 (en) | 2004-11-24 | 2014-06-24 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
| CN101049287A (zh) | 2006-04-07 | 2007-10-10 | 财团法人长庚纪念医院 | 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法 |
| US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
| JP2007308398A (ja) * | 2006-05-17 | 2007-11-29 | Chang Gung Memorial Hospital | 目薬、及びその製造方法 |
| MX2010003774A (es) * | 2007-10-08 | 2010-04-27 | Fovea Pharmaceuticals Sa | Formulaciones oftalmicas acuosas. |
| US8883214B2 (en) | 2009-01-13 | 2014-11-11 | The Regents Of The University Of California | Implantable delivery vehicle for ocular delivery of muscarinic antagonists |
| US20120203161A1 (en) | 2009-08-12 | 2012-08-09 | Seros Medical, Llc | Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use |
| WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
| BR112015017708A2 (pt) * | 2013-01-31 | 2017-07-11 | Senju Pharma Co | solução aquosa estável |
| KR102027663B1 (ko) | 2013-05-06 | 2019-10-01 | 가오슝 창 궁 메모리얼 하스피털 | 약학적 조성물 및 이의 용도 |
| WO2015055301A1 (en) * | 2013-10-15 | 2015-04-23 | Pharmathen S.A. | Preservative free pharmaceutical compositions for ophthalmic administration |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US20160009705A1 (en) * | 2014-06-24 | 2016-01-14 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016013993A1 (en) | 2014-07-25 | 2016-01-28 | Imuneks Farma Llac Sanayi Ve Ticaret A.Ş. | Stable preservative free ophthalmic formulations of opioid antagonists |
| WO2016187426A1 (en) | 2015-05-19 | 2016-11-24 | Amorphex Therapeutics Llc | A device that delivers a sustained low-dose of a myopia-suppressing drug |
| CA2987787C (en) | 2015-06-18 | 2023-06-27 | Presbyopia Therapies, LLC | Compositions for the improvement of distance vision and the treatment of refractive errors of the eye |
| AR108591A1 (es) | 2016-05-25 | 2018-09-05 | Singapore Health Serv Pte Ltd | Composición acuosa que contiene atropina |
| EP3548000B1 (en) * | 2017-05-11 | 2021-11-10 | Vyluma Inc. | Atropine pharmaceutical compositions |
| US11191751B1 (en) | 2020-10-08 | 2021-12-07 | Ads Therapeutics Llc | Topical ophthalmological atropine free base compositions |
-
2018
- 2018-05-10 EP EP18798073.5A patent/EP3548000B1/en active Active
- 2018-05-10 US US15/976,279 patent/US10251875B2/en active Active
- 2018-05-10 LT LTEPPCT/US2018/032017T patent/LT3548000T/lt unknown
- 2018-05-10 MX MX2019013218A patent/MX392558B/es unknown
- 2018-05-10 JP JP2018091739A patent/JP6557379B2/ja active Active
- 2018-05-10 AU AU2018265257A patent/AU2018265257B2/en active Active
- 2018-05-10 SG SG11201910085U patent/SG11201910085UA/en unknown
- 2018-05-10 HR HRP20212019TT patent/HRP20212019T1/hr unknown
- 2018-05-10 ES ES18798073T patent/ES2901140T3/es active Active
- 2018-05-10 HU HUE18798073A patent/HUE056595T2/hu unknown
- 2018-05-10 RS RS20211580A patent/RS62817B1/sr unknown
- 2018-05-10 PL PL18798073T patent/PL3548000T3/pl unknown
- 2018-05-10 RU RU2019139290A patent/RU2745603C1/ru active
- 2018-05-10 KR KR1020197036249A patent/KR102281667B1/ko active Active
- 2018-05-10 SI SI201830521T patent/SI3548000T1/sl unknown
- 2018-05-10 CA CA3063228A patent/CA3063228C/en active Active
- 2018-05-10 WO PCT/US2018/032017 patent/WO2018209051A1/en not_active Ceased
- 2018-05-10 CN CN201880031247.6A patent/CN110621298B/zh active Active
- 2018-05-10 EP EP21205568.5A patent/EP3970694A1/en active Pending
- 2018-05-10 PT PT187980735T patent/PT3548000T/pt unknown
-
2019
- 2019-02-20 US US16/280,384 patent/US10568875B2/en active Active
- 2019-02-20 US US16/280,585 patent/US10610525B2/en active Active
- 2019-02-20 US US16/280,552 patent/US11071732B2/en active Active
- 2019-02-20 US US16/280,669 patent/US10576074B2/en not_active Ceased
- 2019-02-20 US US16/280,405 patent/US10583132B2/en active Active
- 2019-07-11 JP JP2019129403A patent/JP6681502B2/ja active Active
- 2019-07-11 JP JP2019129396A patent/JP6865476B2/ja active Active
- 2019-07-11 JP JP2019129405A patent/JP6681503B2/ja active Active
- 2019-11-11 CL CL2019003228A patent/CL2019003228A1/es unknown
- 2019-11-18 CO CONC2019/0012893A patent/CO2019012893A2/es unknown
- 2019-11-28 PH PH12019502701A patent/PH12019502701A1/en unknown
-
2020
- 2020-07-20 US US16/933,642 patent/US11464769B2/en active Active
- 2020-08-31 US US17/007,816 patent/US11730727B2/en active Active
- 2020-08-31 US US17/007,900 patent/US11730728B2/en active Active
- 2020-09-09 US US17/016,186 patent/US11707458B2/en active Active
-
2021
- 2021-01-11 US US17/145,589 patent/US11642338B2/en active Active
- 2021-03-30 JP JP2021056894A patent/JP7332179B2/ja active Active
- 2021-12-23 CY CY20211101132T patent/CY1124880T1/el unknown
-
2022
- 2022-03-02 US US17/685,286 patent/USRE50040E1/en active Active
-
2023
- 2023-06-28 US US18/343,636 patent/US12036217B2/en active Active
-
2024
- 2024-06-26 US US18/755,212 patent/US20240342154A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502701A1 (en) | Atropine pharmaceutical compositions | |
| MX2024001210A (es) | Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia | |
| MX2016009666A (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
| EP4427808A3 (en) | Compositions and methods for reducing ocular neovascularization | |
| PH12020550341A1 (en) | Niraparib formulations | |
| RU2015141767A (ru) | Композиции и способы для местной доставки простагландинов в подкожный жир | |
| MY196319A (en) | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders | |
| MX2020007945A (es) | Proteinas f del rsv estabilizadas y usos de las mismas. | |
| WO2014188276A3 (en) | Antioxidant compositions and methods of using the same | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| MX2018010788A (es) | Composicion oftalmologica. | |
| ZA202004023B (en) | 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors | |
| CA3030422C (en) | Stabilizing excipients for therapeutic protein formulations | |
| MX2022001719A (es) | Formulaciones de conjugados de benzazepina y usos de las mismas. | |
| WO2015171460A3 (en) | Formulations of cyclophosphamide liquid concentrate | |
| AU2015287920A8 (en) | Micronized Wharton's Jelly | |
| WO2018111315A8 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES | |
| EP4292652A3 (en) | Compounds for the treatment of glycogen storage disorders | |
| MX2019011545A (es) | Composiciones celulares y de andamio inyectables. | |
| PH12016502050A1 (en) | Homovanillinic acid ester, in particular, for creating a hot and/or pungent taste sensation | |
| EA202192322A1 (ru) | Фармацевтические составы | |
| MX2023009676A (es) | Extractos de corteza de abedul que contienen betulina y su formulacion. | |
| WO2016195194A3 (ko) | 신규한 tlr2 길항제 | |
| WO2018062876A3 (ko) | 통증이 경감되는 골관절염 치료용 키트 | |
| MY199547A (en) | Phosphaplatin liquid formulations |